Share-based Payment Arrangement, Expense of Intellia Therapeutics, Inc. from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Intellia Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • Intellia Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $16,739,000, a 58% decline year-over-year.
  • Intellia Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $80,219,000, a 48% decline year-over-year.
  • Intellia Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $80,219,000, a 48% decline from 2024.
  • Intellia Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $154,273,000, a 15% increase from 2023.
  • Intellia Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $134,050,000, a 47% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Intellia Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $80,219,000 $16,739,000 -$22,878,000 -58% 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 $103,097,000 $19,604,000 -$20,015,000 -51% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $123,112,000 $22,036,000 -$18,825,000 -46% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $141,937,000 $21,840,000 -$12,336,000 -36% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $154,273,000 $39,617,000 +$4,574,000 +13% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 $149,699,000 $39,619,000 +$4,267,000 +12% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $145,432,000 $40,861,000 +$4,461,000 +12% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $140,971,000 $34,176,000 +$6,921,000 +25% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $134,050,000 $35,043,000 +$10,417,000 +42% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q3 2023 $123,633,000 $35,352,000 +$10,137,000 +40% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $113,496,000 $36,400,000 +$13,332,000 +58% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $100,164,000 $27,255,000 +$8,764,000 +47% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $91,400,000 $24,626,000 +$10,065,000 +69% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $81,335,000 $25,215,000 +$9,805,000 +64% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $71,530,000 $23,068,000 +$12,454,000 +117% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $59,076,000 $18,491,000 +$12,067,000 +188% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $47,009,000 $14,561,000 +$8,979,000 +161% 01 Oct 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
Q3 2021 $38,030,000 $15,410,000 +$10,010,000 +185% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $28,020,000 $10,614,000 +$5,850,000 +123% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $22,170,000 $6,424,000 +$2,267,000 +55% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $19,903,000 $5,582,000 +$2,566,000 +85% 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $17,337,000 $5,400,000 +$2,321,000 +75% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $15,016,000 $4,764,000 +$360,000 +8.2% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $14,656,000 $4,157,000 -$435,000 -9.5% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $15,091,000 $3,016,000 -$566,000 -16% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $15,657,000 $3,079,000 -$1,377,000 -31% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $17,034,000 $4,404,000 -$497,000 -10% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $17,531,000 $4,592,000 +$485,000 +12% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $17,046,000 $3,582,000 -$3,014,000 -46% 01 Oct 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
Q3 2018 $20,060,000 $4,456,000 +$1,209,000 +37% 01 Jul 2018 30 Sep 2018 10-Q 31 Oct 2019 2019 Q3
Q2 2018 $18,851,000 $4,901,000 +$2,052,000 +72% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $16,799,000 $4,107,000 +$1,477,000 +56% 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1
Q4 2017 $15,322,000 $6,596,000 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
Q3 2017 $3,247,000 +$1,192,000 +58% 01 Jul 2017 30 Sep 2017 10-Q 31 Oct 2018 2018 Q3
Q2 2017 $2,849,000 +$1,016,000 +55% 01 Apr 2017 30 Jun 2017 10-Q 01 Aug 2018 2018 Q2
Q1 2017 $2,630,000 01 Jan 2017 31 Mar 2017 10-Q 01 May 2018 2018 Q1
Q3 2016 $2,055,000 01 Jul 2016 30 Sep 2016 10-Q 31 Oct 2017 2017 Q3
Q2 2016 $1,833,000 01 Apr 2016 30 Jun 2016 10-Q 01 Aug 2017 2017 Q2

Intellia Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $80,219,000 -$74,054,000 -48% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $154,273,000 +$20,223,000 +15% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $134,050,000 +$42,650,000 +47% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
2022 $91,400,000 +$44,391,000 +94% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $47,009,000 +$27,106,000 +136% 01 Jan 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
2020 $19,903,000 +$4,812,000 +32% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $15,091,000 -$1,955,000 -11% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $17,046,000 +$1,724,000 +11% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 $15,322,000 +$8,607,000 +128% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
2016 $6,715,000 +$5,407,000 +413% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
2015 $1,308,000 01 Jan 2015 31 Dec 2015 10-K 14 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.